Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508808-38-00

Acronym

CDR404-001

Enrollment

Registered

2024-04-28

Start date

2024-05-29

Completion date

Unknown

Last updated

2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Denmark, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026